Real Endpoints brings a wide range of strategic and operational market access solutions to our clients.
News and Events
by Real Endpoints LLC
Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving healthcare landscape, announced today that Jeff Berkowitz, a 20-year veteran of the pharmaceutical, drug distribution, pharmacy and payer industries, has joined the company as CEO and member of the board of directors. Jeff is one of the rare executives whose.....
September 13, 2018read full press release >
Speaker: Roger Longman
Real Endpoints LLC
The FH Global Summit is the only conference dedicated to solving global challenges in the care and treatment of familial hypercholesterolemia (FH) through a multi-stakeholder and interdisciplinary approach. An invitation-only event, the summit features a stellar lineup of speakers and panelists who are experts in FH, genomics, precision medicine, alongside leading healthcare practitioners, individuals with FH and industry.
October 1, 2018
October 2, 2018
Marina del Rey, CAevent >
Attendee: Real Endpoints team
The Academy of Managed Care Pharmacy (AMCP) is the nation’s leading professional association dedicated to increasing patient access to affordable medicines, improving health outcomes and ensuring the wise use of health care dollars. Through evidence- and value-based strategies and practices, the Academy’s 8,000 pharmacists, physicians, nurses and other practitioners manage medication therapies for the 270 million Americans served by health plans, pharmacy benefit management firms, emerging care models and government.
October 22, 2018
October 25, 2018
Orlando, FLevent >
by Richard Mark Kirkner
The first gene therapy to treat an inherited disease is out of the gate, but with a very high price tag. Many more gene therapies are on their way. How can they be priced to hit the sweet spot of affordability, access, and innovation?
July 25, 2018
Managed Careread full article >
Recent Insightsview archive >
July 2, 2018
Confirmation bias: when innovators believe in a drug, find the evidence to support its value, and dismiss or ignore the facts challenging their preferred story. Industry and its investors need a clear, objective lens through which they can burn away confirmation bias and see the likely access barriers their drugs will face once approvedRead full insight article >
June 18, 2018
For all of the millions who suffer from depression, the biological underpinnings of clinical depression are still not fully understood. With several high profile approval decisions and possible launches on the horizon, the stage is thus set for an emerging commercial case characterized by a new wave of effective anti-depressants, an increasingly influential assortment of payers and practitioners with generic but often ineffectual pharmacotherapy options at their disposal, and of course patients with an unabating level of need and strikingly high placebo response-rates. How will it play out?read full insight presentation >
National Business Director
Top 5 Pharma
Specialty Access Solutions, Top 5 Pharma
Director of Operations
Reimbursement and Patient Support Services, Top 20 Pharma
Chronis H. Manolis, RPh
Vice President, Pharmacy UPMC Health Plan
President , GlaxoSmithKline U.S.